Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer

(MedPage Today) -- MADRID -- Treatment with tisotumab vedotin (Tivdak) significantly extended overall survival (OS) compared with chemotherapy in patients with recurrent or metastatic cervical cancer, the phase III randomized innovaTV 301 study...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news